Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Zoom Video Communications, Inc. — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Zoom Video Communications, Inc. trades at $93.24 (market cap $28.64B). The key difference: Zoom Video Communications, Inc. is far larger — about 3.8× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Zoom Video Communications, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Zoom Video Communications, Inc. for 92 Days on average.
| SYRE | ZM | |
|---|---|---|
Market Cap | $7.52B | $28.64B |
Volume | 1,441,031 | 2,595,677 |
Sector | Health | Technology |
52-Week High | $108.92 | $111.88 |
52-Week Low | $22.18 | $72.72 |
Typical Hold Time | 0 Days | 92 Days |
Enterprise Value | $6.52B | $21.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Zoom Communications (ZM) trades at $94.47, down 3.54% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $118.08. The company reported strong profitability with a net income margin of 65.19% in 2026 and is advancing its AI-powered revenue OS, positioning for growth amid recent earnings beats.
The stock presents a compelling opportunity given its attractive valuation (P/E of 9.11) and robust fundamentals, though risks include reliance on international sales and competitive pressures in the communication software sector. Upside potential exists if the company executes on its AI initiatives and maintains earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
